3P-MACE: 3-point major adverse cardiac events – All About Cardiovascular System and Disorders
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high ...
Alfonso Valle on X: "Efficacy & safety of SGLT2i/GLP-1RA for CV outcomes: meta-analysis 👥 170930 👉GLP-1RA & SGLT2i ⤵️11% 3P-MACE vs placebo/DPP-4 👉SGLT2i vs GLP-1RA ⛔️difference in 3P-MACE SGLT2i ⤵️ 24% HF🏥
High miR-126-3p levels associated with cardiovascular events in a general population - ScienceDirect
Antihyperglycemic Medications for Cardiovascular Disease Risk Reduction
Impact of Chronic Kidney Disease on the Associations of Cardiovascular Biomarkers With Adverse Outcomes in Patients With Suspected or Known Coronary Artery Disease: The EXCEED‐J Study | Journal of the American Heart
3P-MACE including cardiovascular death, myocardial infarction, and... | Download Scientific Diagram
Cardiovascular outcomes that will change diabetes practice: What are the key findings from recent trials? Prof. Mark Cooper, MD
Endocrinologist Perspective
3P-MACE Event Rates in CVOTs (Placebo Groups) | Download Scientific Diagram
3P-MACE Event Rates in CVOTs (Placebo Groups) | Download Scientific Diagram
CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle - ScienceDirect
EMPRISE study outcomes of interest. 3P‐MACE: three‐point major... | Download Scientific Diagram
Pharmedu
Abbreviations 3P-MACE: 3-point major adverse cardiovascular events;... | Download Scientific Diagram
Risk factors and goal achievement related to 3P-MACE. | Download Scientific Diagram
Risk factors and goal achievement related to 3P-MACE. | Download Scientific Diagram
3P-MACE by baseline CVD history. The forest plot shows hazard ratios... | Download Scientific Diagram
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy CREDENCE Trial | PDF | Chronic Kidney Disease | Renal Function
Cardiovascular Outcome Trial (CVOT) - Tradjenta® (linagliptin)
Cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in Asians with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials - ScienceDirect
Swapnil Hiremath @hswapnil@med-mastodon.com on X: "High risk patients MACE primary outcomes Key secondary = renal (presented today) #KidneyWk Non-inferiority design https://t.co/PlHAHhXhcl" / X
Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clini
Diabetes and cardiovascular disease: it's time to apply the evidence - Peter J Grant, Nikolaus Marx, 2020
